• Genetic TherapyEnrolling

  Study to evaluate VX-522 in adults 18 years and older with cystic fibrosis. , protocol number Vertex VX-522-001 MAD (VX21-522-001)

  This study will evaluate the safety and tolerability of VX-522, an investigational inhaled messenger RNA (mRNA) therapy, in adults with CF whose mutations are not responsive to CFTR modulator therapy.

  • Age:

    18 Years to 65 Years

  • Mutation(s):

    No Copies F508del

  • FEV1% Predicted:

    40 to 90%

  • Number of Visits:

    27

  • Length of Participation:

    8 months

• Restore CFTR ProteinEnrolling

  Phase 3 study of VX-121/tezacaftor/deutivacaftor in children ages 2 to 5 with cystic fibrosis , protocol number Vertex VX21-121-105 Cohort B2

  This study is taking place at multiple care centers across the U.S. It will look at the safety and tolerability and how the body processes the drug VX-121/tezacaftor/deutivacaftor in participants with at least one triple-combination responsive CF mutation. 

  • Age:

    2 Years to 5 Years

  • Mutation(s):

    Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    8

  • Length of Participation:

    32 weeks

• Anti-InflammatoryEnrolling

  Study to evaluate BI 1291583 in adults with bronchiectasis , protocol number BI 1397-0014 (Airtivity)

  This study will test the effectiveness, safety, and tolerability of BI 1291583, a drug intended to reduce inflammation in the lungs.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    9

  • Length of Participation:

    76 weeks

• Anti-InfectiveEnrolling

  Study to evaluate the standardizing of treatment for pulmonary exacerbations in children and adults with CF ages 6 and older. , protocol number STOP360-IP-22

  This study will look at pulmonary exacerbations, which are a worsening of respiratory symptoms, in people with CF who need to be treated with intravenous (IV) antibiotics. It will compare treatment with one antibiotic (a beta-lactam) to treatment with two antibiotics (tobramycin and a beta-lactam) to learn whether there is a difference in lung function and symptom improvement between the two groups. This study is for people ages 6 and older.

  • Age:

    6 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    48 days

• ObservationalEnrolling

  An observational study of health outcomes of parents with cystic fibrosis (HOPE CF) , protocol number KAZMER22A0

  The HOPeCF observational study will evaluate the impact of parenthood on the health of people with CF.

  • Age:

    18 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    1

  • Length of Participation:

    5 years

• OtherEnrolling

  A study to evaluate the insulin-only Bionic Pancreas in people with cystic fibrosis 14 years of age or older who have cystic fibrosis-related diabetes (CFRD) , protocol number Bionic Pancreas CFRD IOBP V 1.0.

  This study will evaluate the effectiveness and safety of using the insulin-only Bionic Pancreas (BP) system compared to using one’s usual insulin delivery method.

  • Age:

    14 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    4

  • Length of Participation:

    7 months

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.